Hebbian Bio

Hebbian Bio is proud to announce its acceptance into the latest cohort of the Merck Digital Sciences Studio (MDS Studio), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer support for early-stage biomedical startups providing strategic guidance, direct investment, and connection opportunities within Merck. Hebbian Bio is pioneering #AI-driven molecular #precision discovery of an untapped layer of neurobiology to enable the development of #drugs and companion diagnostics/patient stratification for better clinical trial design for #neurodevelopmental and #neuropsychiatric conditions. This opportunity marks a significant milestone, as we continue to develop our #techbio platform, and a real boost for us as an early stage neuro precision startup that generates data sets and IP entirely in-house.  About Merck Digital Sciences Studio The Merck Digital Sciences Studio (MDS Studio or MDSS) is a collaboration between Merck, the Merck Global Health Innovation Fund, Northpond Ventures, McKesson Ventures, Microsoft for Startups, and the New Jersey Innovation Institute, a New Jersey Institute of Technology (NJIT) subsidiary. The 10-month startup accelerator program empowers members and enables the generation of innovative digital technologies for drug discovery and development through hands-on mentorship, connection opportunities with industry-leading partners, and training in an active entrepreneurial setting. Through the accelerator program, these startups will have access to workshops, coaching, office space, and Microsoft for Startups resources, including up to $150,000 Azure Cloud computing credits. We are excited to be among a stellar cohort of 12 startups and mentors at the forefront of developing next-gen models, tools, and technologies to accelerate drug development for the benefit of patients: Nine Diagnostics, Augment Biologics, Esya Labs, ImYoo, Inaedis, Inc., ModernVivo, Potato AI, ReSync Bio, UbiquiTx, Inc., Voyant Bio & Anita Manik, MBA, CPA, Ahmet Hamdi Cavusoglu, Brittany Ryan, Christopher Ghadban, Christopher Woelk, Erum Azeez Khan, Matt Doherty, Sangeetha Ramsagar! We will be at #JPM25 and look forward to connecting with operators interested in the neuro space. Please reach out!

Looking forward to taking part in this panel on the role of AI in life sciences and careers in the NYC life sciences ecosystem #neuroprecision #CNS #precisionpsychiatry

PhD scientists often don’t get to see the patients who are affected by the conditions they study. It has been transformative to regularly meet and interact with patients and their families for us. We had the privilege to take part in this year’s Project 8p Foundation science conference and spend time with 8p heros and their families over breakfast, lunch, dinner, and dancing, and we learned so much 💫🙏🏼 Project 8p Foundation is a pioneer on many fronts, including their openness to novel technologies. Thank you for being our 1st pilot partner in utilizing Hebbian Bio’s neuroprecision platform for drug #target and #biomarker discovery #precisionpsychiatry #neurodevelopmentaldisorders #autism #schizophrenia #adhd #raredisease #neuro #CNS #precisionhealth #precisionmedicine

It was a privilege to attend the 2024 Precision Health Summit together with a group of leaders in the #precision health and medicine space, last week in NYC. Key takeaways: 💡in the past year, 38% of all FDA-approved drugs were precision medicine, utilizing biomarkers 💡2/3 of all drugs in pharma-driven clinical trials are categorized as precision medicine Precision medicine as an approach is clearly working in cancer and is here to stay. At Hebbian Bio, we are focused on neuro conditions by building a neuro-precision platform for better drug target identification and patient stratification. Much of our work is centered on neurodevelopmental disorders, some of which are currently classified as #rare, a concept that will be obsolete as precision medicine advances. Hebbian Bio is making “rare” less rare.

📢 Connect with WCBA alum in person next Wednesday! We're thrilled to invite you to an engaging panel discussion led by FirstXFounder Alums. This event is a unique opportunity to dive deep into the 2025 WCBA application process and connect directly with the WCBA program team. 🔗 - https://lu.ma/frrii3r8 🗓️ Date & Time: August 28, 6 - 7:30 PM 📍 Location: Mortimer B. Zuckerman Research Center Why you should attend: 💡 Gain insights from FXF Alums and experiences #entrepreneurs 💡 Learn key details about the 2025 WCBA application process 💡 Connect in-person with the WCBA program team and get your questions answered! The WCBA program supports academic and corporate spinouts, inventors, and first-time founders in building emergent ventures. Don’t miss this chance to network and learn from the best in the industry. 🤝 Co-hosted by: The Tri-Institutional Startup Venture Group, TRIBC, and BiotechXYZ Speakers: Hourinaz Behesti, Founder: Hebbian Bio Paul Booth, Applied Surgical Robotics Prakrit Jena, Lime Therapeutics 👥 Shoutout to: Nick Bartello, Margaret Hoang, Thasin Peyear, Raquel Castromonte, Annalisa Ferrotta Join us and take a significant step towards your entrepreneurial journey! 🌟 #Biotech #WCBA2025 #Startup #Innovation #Networking

This was the best way to get started! We are grateful for all the learnings, opportunities, and the community that helped accelerate our path in pursuing our mission to bring first-in-class treatments for #neurodevelopmental conditions #nycbiotech #neuroprecision

It’s Patient Advocacy Group conference season! We recently took part in the CACNA1A Foundation patient and scientist research round table at the National Institute of Neurological Disorders and Stroke (NINDS). We learned so much from spending time with the patients. Lots of cool new initiatives on how to better quantify movement, speech, and overall progression to help find the right treatment for the right patient. “A key takeaway was that to achieve our mission of finding better treatments and a cure for CACNA1A-related disorders, we must continue the strong partnership between the families, the CACNA1A Foundation, and the Research Network. Families provide the information and tools to understand our disease. Researchers utilize these assets to develop and test treatments. And, the Foundation bridges these two communities, supporting and holding them together to move forward” 💯

Primetime for #neuropsychiatric symptoms: “The Lancet Psychiatry forecasts that 1/2 of the global population will experience a mental health disorder in their lifetime. Yet current treatments fall short for up to 1/3 of the patients. There are two paths ahead for innovation: design better drugs for established targets or find entirely new biological mechanisms” Hebbian Bio is doing the latter. Our focus is on #neurodevelopmentalDisorders 💡The global mental health treatment market is expected to exceed $500 B by 2028.

See you there NYC #startup #nycbiotech #precisionCNS

ONLY 48 HOURS AWAY: The 12th Annual WCBA & ABCT Pitch Day in Midtown Manhattan! Get your tickets today: https://lnkd.in/gdWPVsSQ Learn more about first-time founders who will share their groundbreaking solutions during Pitch Day: WCBA: Westchester County Biosciences Accelerator (The Catalyst) Anita Lee - Twin Weavers Ariel Y. (Ariel Yusupov), New York Medical College, FIG Therapeutics, Inc. Inc Daniel S. Gareau, The Rockefeller University, SurgiVance Inc Evris Gavathiotis, Albert Einstein College of Medicine, BaxGen Therapeutics Glen Prusky, Weill Cornell Medicine, Gaze Engine Hourinaz Behesti, Rockefeller University, Hebbian Bio Ilya Popov, MBA, Independent, ComeBack Mobility Dr. Katia M. R. (Katia Rojas), Independent, Suabix Kirsten Hund Blair and Kevin McClarren, Independent, Lambent Data, Inc. Zach S. (Zach Sawaged), Independent, Concordare ABCT: Accelerator for Biosciences in Connecticut Courtney K Rowe, MD, Christopher Foster, and Kelly Burke, University of Connecticut, Pallivex Joshua Gilmore, Independent, Social Health Passport Julien Berro and Yuan Ren, Yale University, Nanochuk Ming Hui, Indepedent, Mobabbi Prisca Obi, Yale University, Virtus Therapeutics Vanessa Sena and Helen Wu, Independent, My Local Chefs